Skip to main content
. 2015 Feb 27;5(6):597–608. doi: 10.7150/thno.11546

Figure 2.

Figure 2

(A) In vivo NIRF imaging of 4T1 tumor-bearing BALB/c normal mice at 2, 8, 24, and 48 h after intravenous injection of Dye-anti-CD206 or Dye-IgG. Tumors are indicated by the dashed circles. (B) Quantification and kinetics of in vivo tumor targeting characteristics of Dye-anti-CD206 or Dye-IgG. (C) Representative images of dissected organs of 4T1 tumor-bearing mice sacrificed at 24 h after intravenous injection of Dye-anti-CD206 or Dye-IgG. (D) Quantified biodistribution of Dye-anti-CD206 and Dye-IgG in 4T1 tumor-bearing mice at 24 h postinjection. *, P <0.05; **, P <0.01.